神经痛治疗市场规模，分享和趋势分析报告，通过治疗（基于药物[抗惊厥药物，三环抗抑郁药]，手术[气球压缩，甘油注射，射频热病变，立体定向放射外科，微血管减压]）;通过最终使用;按地区和分部预测，2020 - 2027

Report Summary

全球神经痛治疗市场于2019年估值为17.8亿美元，预计预计预测期内的复合年增长率为6.1％。推动神经痛市场增长的因素包括成年人和老年人的有关问题的高发病率，糖尿病人群的普遍性，持续研究神经退行性条件，资金和工业学术协作。有多种神经退行性条件如多发性硬化，其中个体自身的免疫系统攻击本身导致形成神经痛。

According to the American Diabetes Association (ADA), approximately 34.1 million U.S. citizens were suffering from diabetes, representing 10% of the entire population. It is also being reported that over 1.6 million U.S. people suffered from Type-I diabetes, with prevalence being higher in old age population.

Know more about this report:请求样本页面

行业动态

成长司机
随着神经系统障碍最容易发生的群体，包括多发性硬化，预计，随着这种群体最容易产生的，增加了治疗需求的增加的老年人口和不规则的生活方式。人口老龄化，在大多数成熟经济体都有高可支配收入，政府赞助的社会保障措施，以及飙升的保险渗透率有望推动对三叉神经痛和神经痛治疗的需求。

According to the estimates, of the National Institute of Neurological Disorders and Stroke (NINDS), each year approximately 12 per 100,000 new cases were recorded with the condition more prevalent in women as compared to men. Among adults, the cause of the disorder is mostly idiopathic, but in comparison to old age population, adults suffer with damage to the central nervous system, although the trigeminal neuralgia or neuralgia condition is rare in children.

According to the estimates of Multiple Sclerosis Trust (MST), based in the U.K, in 2020, over 2.5 million people were suffering from multiple sclerosis (ML), across the globe. Moreover, according to the internal estimates of Public Health England (PHE), in 2018, the prevalence rate of ML across England (190), Scotland (290), Wales (179), and Northern Ireland (258) were recorded per ten thousand of population. It is also being reported that the prevalence of ML has risen over the past decade. Such new cases of ML are expected to boost the sale of neuralgia and trigeminal neuralgia treatment and drugs.

神经痛治疗市场报告范围

该市场主要基于治疗，最终用途和地区进行细分。

By Treatment	By End-Use	By Region
药物基础 抗惊厥药物 carbamazepine§oxcarbazepine. Topiramate Gabapentin Pregabalin clonazepam. 苯妥IN. Lamotrigine 丙戊酸 Tricyclic Antidepressants amittiptyline. NORTRIPTYLINE. Surgeries Balloon Compression 甘油注射 射频热损伤 Stereotactic Radiosurgery 微血管减压	Hospitals & Clinics Ambulatory Surgery Centers 其他	North America (U.S., Canada) Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria) Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea) 拉丁美洲(巴西、墨西哥、基于“增大化现实”技术gentina) Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report:请求样本页面

Insight by Treatment

Based on treatment, the global market is categorized into drug based and surgeries. Drug based treatment further classified as anticonvulsant medicines and tricyclic anti-depressants. Anticonvulsant medicine further segmented into Carbamazepine, Oxcarbazepine, Topiramate, Gabapentin, Pregabalin, Clonazepam, Phenytoin, Lamotrigine, and Valproic Acid. Tricyclic Antidepressants sub-segmented as Amitriptyline, and Nortriptyline.

2019年，手术部门占收入最高份额，并且可能在预计期间持续占主导地位。这可能归因于对可用治疗方案的意识提高，以及替代手术的高成本，这对于各国大多数人口昂贵。因此，预计对神经痛和三叉神经痛的需求将见证生长。

最终用途的洞察

Based on end-use, the neuralgia treatment market is segmented into hospitals & clinics, ambulatory surgery centers, and others. Hospitals & clinics segment accounted for the highest revenue share. The increasing neuralgia and trigeminal neuralgia surgeries, availability of drugs, and strategic collaborations with the drug makers is likely to drive market growth.

地理概述

地理上，北美占2019年最大的收入份额。增加了三叉神经痛，关键参与者的出现以及美国和加拿大有利的偿还情景的发病率增加，预计将推动北美的需求。此外，与优秀的医疗基础设施和医学素质相结合的治疗方案的可用性可能会补充神经痛和三叉神经痛治疗市场。

According to the National Organization for Rare Disorders (NORD), each year in the U.S. on an average 135,000 new cases of trigeminal neuralgia were reported. Moreover, according to estimates of NCBI, the annual incidence of TN is around 12.4 per 100 thousand of population, and it increases for the old age people.

Competitive Insight

经营全球市场的主要参与者包括Allergan Plc，Glaxosmithkline Plc。，Biogen，Inc。，Abbott Laboratories，Pixarbio Corporation，Merz Pharma GmbH，Trigemina Inc.，Pfizer Inc.，Novartis，Lupine等。

Companies in the market are focused on developing non-invasive treatment procedures to gain competitive advantage. For instance, in February 2019, Zydus received market approval for its Carbamazepine, prescribed for the treatment of the trigeminal neuralgia.